Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07636863 · ClinicalTrials.gov registry record
Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 200
- Enrollment target
NCT07636863: Completed study, sponsored by Bristol-Myers Squibb.
NCT07636863 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07636863 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This study will review medical records of adults with cancer who received nivolumab either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection in community oncology clinics in the United States. The study will describe who receives each type of treatment, how the treatments are used, and selected safety events such as reactions at the injection or infusion site and infections.
Interventions
- DRUG Nivolumab
- COMBINATION_PRODUCT Subcutaneous nivolumab combined with hyaluronidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-08-21 |
| Est. Completion | 2026-03-27 |
What the finished NCT07636863 record still lists
NCT07636863 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT07636863 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07636863 about?
NCT07636863 is a clinical study titled "Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig". This study will review medical records of adults with cancer who received nivolumab either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection in community oncology clinics in the United States. The study will describe who receives each type of treatment, how the treatmen...
What is the current status of trial NCT07636863?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2025-08-21. Estimated completion is 2026-03-27.
What interventions are being tested in trial NCT07636863?
The interventions under investigation include: Nivolumab (DRUG), Subcutaneous nivolumab combined with hyaluronidase (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07636863?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI